Identification | Back Directory | [Name]
RU-301 | [CAS]
1110873-99-8 | [Synonyms]
RU-301 RU 301;RU301 Benzamide, 2-[[(3-methyl-5-isoxazolyl)methyl]thio]-N-[2-[[2-nitro-4-(trifluoromethyl)phenyl]amino]ethyl]- | [Molecular Formula]
C21H19F3N4O4S | [MDL Number]
MFCD11802385 | [MOL File]
1110873-99-8.mol | [Molecular Weight]
480.46 |
Chemical Properties | Back Directory | [Boiling point ]
661.0±55.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (520.33 mM) | [form ]
Solid | [pka]
13.86±0.46(Predicted) | [color ]
Light yellow to khaki |
Hazard Information | Back Directory | [Uses]
RU-301 is a pan-TAM receptor (Axl, Tyro3 and Mertk) inhibitor that blocks the Axl receptor dimerization site. | [in vivo]
RU-301 (100, 300 mg/kg; i.p.; single daily for 4 days) inhibits tumor growth in lung cancer xenograft model[1]. RU-301 (300 mg/kg; i.p.; 3 times a week for 4 weeks) reduces liver fibrosis in mice[2]. Animal Model: | NOD/SCIDγ mice (4-6 week; lung cancer xenograft model)[1]. | Dosage: | 100, 300 mg/kg | Administration: | Intraperitoneal injection; single daily for 4 days | Result: | Significantly decreased tumor volume while body weights were not significantly different.
Showed no notable toxicity but displayed good bioavailability with a t1/2 life of ~7-8 hours.
|
Animal Model: | WT or Mertk?/? male mice (fed NASH diet for 12 weeks)[2]. | Dosage: | 300 mg/kg | Administration: | Intraperitoneal injection; 3 times a week for 4 weeks | Result: | Reduced liver fibrosis as indicated by decreases in liver picrosirius red staining and collagen gene expression. |
|
|
Company Name: |
InvivoChem
|
Tel: |
13549236410 |
Website: |
https://www.invivochem.cn/ |
|